Who
Robert Chess
Director
Company insider
Files Form 4 as: Chairman of the Board, Nektar Therapeutics; Director, Twist Bioscience; Director, Cotherix.
In numbers
- Trades disclosed
- 223
- Buys
- 0
- Sells
- 54
- Bought
- $0
- Sold
- $18.2M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 3 Jan 2006
- Last trade
- 23 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Code M | $219K18,417 at $11.89 | filing |
| 7 Aug 2026filed 11 Aug 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $2.0M18,417 at $110.89 | filing |
| 7 Aug 2026filed 11 Aug 2026 | TWST Twist Bioscienceoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —18,417 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | TWST Twist Bioscienceoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —18,417 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Code M | $219K18,417 at $11.89 | filing |
| 7 Aug 2026filed 11 Aug 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $2.0M18,417 at $110.89 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Code M | $119K10,000 at $11.89 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $470K10,000 at $47.00 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TWST Twist Bioscienceoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TWST Twist Bioscienceoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Code M | $119K10,000 at $11.89 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $470K10,000 at $47.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $105K2,184 at $48.26 | filing |
| 13 Feb 2026filed 18 Feb 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $105K2,184 at $48.26 | filing |
| 5 Feb 2026filed 9 Feb 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Code A | —5,095 at $0.00 | filing |
| 5 Feb 2026filed 9 Feb 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Code A | —5,095 at $0.00 | filing |
News
Twist Bioscience (NASDAQ:TWST) versus Quanterix (NASDAQ:QTRX) Financial AnalysisTWST · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Robert Chess; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.